FDA approves 1st needle-free alternative to EpiPens

There's now an option to treat anaphylaxis via a nasal spray, rather than with an auto-injected medication.

An image showing the packaging of the nasal spray device
There's one dose of the medicine in each nasal-spray bottle.
(Image credit: ARS Pharmaceuticals, Inc.)

The Food and Drug Administration (FDA) has approved the first needle-free treatment for the life-threatening allergic reaction anaphylaxis.

In a statement released Friday (Aug. 9), the FDA announced it had approved Neffy, a nasal-spray formulation of epinephrine. That's the same medication found in EpiPens.

Nicoletta Lanese
Channel Editor, Health

Nicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She is a recipient of the 2026 AHCJ International Health Study Fellowship, with a project focused on antibiotic stewardship practices in Japan and the U.S. They hold a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida. Beyond Live Science, Lanese's work has appeared in The Scientist, Science News, the Mercury News, Mongabay and Stanford Medicine Magazine, among other outlets. Based in NYC, she also remains involved in dance and performs in local choreographers' work.